Neurogranin and Neuronal Pentraxin Receptor As Synaptic Dysfunction Biomarkers in Alzheimer's Disease

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Oct 13

PMID 34640593

Citations 11

Authors

Maciej Dulewicz

Agnieszka Kulczynska-Przybik

Agnieszka Slowik

Renata Borawska

Barbara Mroczko

Affiliations

Soon will be listed here.

Abstract

Methods: Ng, NPTXR and classical AD biomarkers concentrations were measured in the CSF of patients with AD and non-demented controls (CTRL) using an enzyme-linked immunosorbent assay (ELISA) and Luminex xMAP technology.

Results: The CSF level of Ng was significantly higher, whereas the NPTXR was significantly lower in the AD patients than in cognitively healthy controls. As a first, we calculated the NPTXR/Ng ratio as an indicator of synaptic disturbance. The patients with AD presented a significantly decreased NPTXR/Ng ratio. The correlation was observed between both proteins in the AD and the whole study group. Furthermore, the relationship between the Ng level and pTau181 was found in the AD group of patients.

Conclusions: The Ng and NPTXR concentrations in CSF are promising synaptic dysfunction biomarkers reflecting pathological changes in AD.

Citing Articles

Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort.

Zeng X, Sehrawat A, Lafferty T, Chen Y, Rawat M, Kamboh M Alzheimers Dement. 2025; 21(2):e14535.

PMID: 39989429 PMC: 11848535. DOI: 10.1002/alz.14535.

Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.

Zanghi A, Greco A, Giancipoli E, Tumani H, Avolio C, DAmico E J Neurol. 2025; 272(2):109.

PMID: 39812684 PMC: 11735525. DOI: 10.1007/s00415-024-12797-0.

Analyzing the potential of neuronal pentraxin 2 as a biomarker in neurological disorders: A literature review.

Ansari U, Wen J, Syed B, Nadora D, Sedighi R, Nadora D AIMS Neurosci. 2025; 11(4):505-519.

PMID: 39801792 PMC: 11712228. DOI: 10.3934/Neuroscience.2024031.

Navigating the Alzheimer's Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics.

El Abiad E, Al-Kuwari A, Al-Aani U, Al Jaidah Y, Chaari A Cells. 2024; 13(22).

PMID: 39594648 PMC: 11593284. DOI: 10.3390/cells13221901.

Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer's disease.

Zeng X, Lafferty T, Sehrawat A, Chen Y, Ferreira P, Bellaver B Mol Neurodegener. 2024; 19(1):68.

PMID: 39385222 PMC: 11465638. DOI: 10.1186/s13024-024-00753-5.

References

Zhabotinsky A, Camp R, Epstein I, Lisman J . Role of the neurogranin concentrated in spines in the induction of long-term potentiation. J Neurosci. 2006; 26(28):7337-47. PMC: 6674191. DOI: 10.1523/JNEUROSCI.0729-06.2006. View

Mango D, Saidi A, Cisale G, Feligioni M, Corbo M, Nistico R . Targeting Synaptic Plasticity in Experimental Models of Alzheimer's Disease. Front Pharmacol. 2019; 10:778. PMC: 6646937. DOI: 10.3389/fphar.2019.00778. View

Clarke M, Brinkmalm A, Foiani M, Woollacott I, Heller C, Heslegrave A . CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. Alzheimers Res Ther. 2019; 11(1):105. PMC: 6918699. DOI: 10.1186/s13195-019-0564-2. View

Gengler S, Hamilton A, Holscher C . Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS One. 2010; 5(3):e9764. PMC: 2842299. DOI: 10.1371/journal.pone.0009764. View

Park S, Han S, Kim C . New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease. Exp Mol Med. 2020; 52(4):556-568. PMC: 7210893. DOI: 10.1038/s12276-020-0418-9. View

Chapman P, White G, Jones M, MARSHALL V, Irizarry M, Younkin L . Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999; 2(3):271-6. DOI: 10.1038/6374. View

Sia G, Beique J, Rumbaugh G, Cho R, Worley P, Huganir R . Interaction of the N-terminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. Neuron. 2007; 55(1):87-102. DOI: 10.1016/j.neuron.2007.06.020. View

Kvartsberg H, Duits F, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K . Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 2014; 11(10):1180-90. DOI: 10.1016/j.jalz.2014.10.009. View

Acquarone E, Argyrousi E, van den Berg M, Gulisano W, Fa M, Staniszewski A . Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade. Mol Neurodegener. 2019; 14(1):26. PMC: 6598340. DOI: 10.1186/s13024-019-0326-4. View

10.

Falgas N, Ruiz-Peris M, Perez-Millan A, Sala-Llonch R, Antonell A, Balasa M . Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. Hum Brain Mapp. 2020; 41(8):2004-2013. PMC: 7267898. DOI: 10.1002/hbm.24925. View

11.

Boros B, Greathouse K, Gentry E, Curtis K, Birchall E, Gearing M . Dendritic spines provide cognitive resilience against Alzheimer's disease. Ann Neurol. 2017; 82(4):602-614. PMC: 5744899. DOI: 10.1002/ana.25049. View

12.

Pereira J, Westman E, Hansson O . Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. Neurobiol Aging. 2017; 58:14-29. DOI: 10.1016/j.neurobiolaging.2017.06.002. View

13.

Hoover B, Reed M, Su J, Penrod R, Kotilinek L, Grant M . Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010; 68(6):1067-81. PMC: 3026458. DOI: 10.1016/j.neuron.2010.11.030. View

14.

Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton N, Blennow K . Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomark Insights. 2020; 15:1177271920950319. PMC: 7444114. DOI: 10.1177/1177271920950319. View

15.

Xu D, Hopf C, Reddy R, Cho R, Guo L, Lanahan A . Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity. Neuron. 2003; 39(3):513-28. DOI: 10.1016/s0896-6273(03)00463-x. View

16.

Lambert M, Barlow A, Chromy B, Edwards C, Freed R, Liosatos M . Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998; 95(11):6448-53. PMC: 27787. DOI: 10.1073/pnas.95.11.6448. View

17.

Blennow K . A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. Neurol Ther. 2017; 6(Suppl 1):15-24. PMC: 5520819. DOI: 10.1007/s40120-017-0073-9. View

18.

Pak J, Huang F, Li J, Balschun D, Reymann K, Chiang C . Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice. Proc Natl Acad Sci U S A. 2000; 97(21):11232-7. PMC: 17183. DOI: 10.1073/pnas.210184697. View

19.

Pasinelli P, Ramakers G, Urban I, Hens J, Oestreicher A, De Graan P . Long-term potentiation and synaptic protein phosphorylation. Behav Brain Res. 1995; 66(1-2):53-9. DOI: 10.1016/0166-4328(94)00124-x. View

20.

Murray M, Graff-Radford N, Ross O, Petersen R, Duara R, Dickson D . Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011; 10(9):785-96. PMC: 3175379. DOI: 10.1016/S1474-4422(11)70156-9. View